Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$27,000.00
Investigating the Role of Prosaposin in Liver Fibrosis
EF 2024-25
Résumé
Chronic liver disease (CLD) is a leading cause of death in Canada, causing significant harm by damaging the liver over time. One of the critical problems in CLD is liver fibrosis, which is the buildup of scar tissue in the liver. This occurs when immune cells called macrophages in the liver activate hepatic stellate cells (HSCs). These HSCs begin to produce excessive collagen, which leads to liver scarring. Liver fibrosis is the strongest predictor of death in patients with CLD, but there are no effective treatments for advanced liver fibrosis. Our research group has identified a protein called prosaposin (PSAP), which is important the metabolism of a specific class of lipids called sphingolipids. These lipids are essential for normal liver function and repair after injury, but during CLD, sphingolipids become dysregulated, worsening liver damage and fibrosis. Our preliminary results show that reducing PSAP in cultured human HSCs decreases collagen production, suggesting that PSAP may be involved in liver fibrosis. We hypothesize that PSAP deficiency in HSCs reduces liver fibrosis severity by modulating collagen production and inflammatory responses. This project aims to investigate how PSAP contributes to liver fibrosis in vivo through its role in HSCs. Using a genetically modified mouse model deficient in PSAP in the HSCs, mice will be treated with carbon tetrachloride (CCl4) to induce liver fibrosis. Liver tissues will be analyzed for collagen accumulation, macrophage infiltration, and HSC gene and protein expression changes. Blood samples will be analyzed for liver injury markers and liver fibrosis-associated proteins. The results will provide valuable insights into PSAP as a therapeutic target for liver fibrosis and clarify its role in disease progression.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
530381
Name
Getachew Aaron
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Role of Prosaposin in Liver Fibrosis
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chronic Liver Disease; Hepatic Stellate Cells; Inflammation; Lipid Metabolism; Liver Fibrosis; Prosaposin; Sphingolipids
Abstract
Chronic liver disease (CLD) is a leading cause of death in Canada, causing significant harm by damaging the liver over time. One of the critical problems in CLD is liver fibrosis, which is the buildup of scar tissue in the liver. This occurs when immune cells called macrophages in the liver activate hepatic stellate cells (HSCs). These HSCs begin to produce excessive collagen, which leads to liver scarring. Liver fibrosis is the strongest predictor of death in patients with CLD, but there are no effective treatments for advanced liver fibrosis. Our research group has identified a protein called prosaposin (PSAP), which is important the metabolism of a specific class of lipids called sphingolipids. These lipids are essential for normal liver function and repair after injury, but during CLD, sphingolipids become dysregulated, worsening liver damage and fibrosis. Our preliminary results show that reducing PSAP in cultured human HSCs decreases collagen production, suggesting that PSAP may be involved in liver fibrosis. We hypothesize that PSAP deficiency in HSCs reduces liver fibrosis severity by modulating collagen production and inflammatory responses. This project aims to investigate how PSAP contributes to liver fibrosis in vivo through its role in HSCs. Using a genetically modified mouse model deficient in PSAP in the HSCs, mice will be treated with carbon tetrachloride (CCl4) to induce liver fibrosis. Liver tissues will be analyzed for collagen accumulation, macrophage infiltration, and HSC gene and protein expression changes. Blood samples will be analyzed for liver injury markers and liver fibrosis-associated proteins. The results will provide valuable insights into PSAP as a therapeutic target for liver fibrosis and clarify its role in disease progression.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Getachew, Aaron
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~